T1	intervention 205 234	heart failure pharmacotherapy
T2	No-of-participants 739 765	One hundred and fifty-nine
T3	eligibility 766 824	patients with histologically confirmed HER2+ breast cancer
T4	intervention 999 1052	angiotensin-converting enzyme inhibitor (perindopril)
T5	intervention 1054 1079	beta-blocker (bisoprolol)
T6	control 1084 1091	placebo
T7	duration 1139 1145	1 year
T8	condition 247 295	trastuzumab-mediated left ventricular remodeling
T9	outcome-Measure 1549 1605	12 month change in left ventricular end-diastolic volume
T10	outcome-Measure 1671 1726	evolution of left ventricular remodeling on cardiac MRI
T11	outcome-Measure 1861 1940	presence of myocardial injury and apoptosis on serum biomarkers and cardiac MRI
T12	outcome-Measure 1949 2080	correlate cardiac biomarkers of myocyte injury and extra-cellular matrix remodeling with left ventricular remodeling on cardiac MRI
